Storia in 2 fonti

Quest Shines As Deals With Hims, Oura Bolster Consumer Biz

Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division.

Raccontata da

investors.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo22 g fa

Quest Shines As Deals With Hims, Oura Bolster Consumer Biz

Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division.

originale

benzinga.com22 g fa

Quest Diagnostics Stock Hits 52-Week High - Here's Why - Quest Diagnostics (NYSE:DGX)

Quest Diagnostics beat Q2 with $3.12 EPS (vs. $2.83 consensus) and $3.043B revenue on 10% organic growth, raising FY2026 guidance to $11.05–$11.25 per share. Sustained growth across consumer wellness and enterprise partnerships signals expanding healthcare digitalization—shifting preventive care diagnostics spend and reshaping IT budget allocations for healthcare enterprises.

Leggi questa versione →

Timeline cronologica

giovedì 23 luglio 2026·investors.com
Quest Shines As Deals With Hims, Oura Bolster Consumer Biz
Quest Diagnostics put up a definitive beat Thursday, driven by solid demand across its consumer division.
giovedì 23 luglio 2026·benzinga.com
Quest Diagnostics Stock Hits 52-Week High - Here's Why - Quest Diagnostics (NYSE:DGX)
Quest Diagnostics (NYSE: DGX) stock jumps after Q2 earnings beat estimates and full-year 2026 guidance gets a boost.